NasdaqGM:NTLABiotechs
Assessing Intellia Therapeutics (NTLA) Valuation As Pivotal HAELO Phase 3 CRISPR Data Approaches
Why Intellia’s upcoming HAELO data release matters for shareholders
Intellia Therapeutics (NTLA) is in focus as investors await topline results from its global Phase 3 HAELO trial of lonvoguran ziclumeran in hereditary angioedema, the first Phase 3 readout for an in vivo CRISPR therapy.
The company plans to share the data and host a webcast on April 27, 2026. This single event could influence sentiment around its broader gene editing pipeline and long term development plans.
See our latest...